Fudan University Shanghai Cancer Center ( Site 2908)

Shanghai, Shanghai Municipality 200032

0 studies enrolling now · 2 studies all time

What they study most

Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Small Cell Lung Carcinoma

Studies at this site

• A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) — Completed
• Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) — Running, not enrolling